{"schema_version":"1.0","type":"article","title":"藥華藥買下予宇，下一步讓細胞造藥？","url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.md","lang":"zh-Hant","date":"2026-10-03","publish_at":"2026-10-03T20:00:00+08:00","updated_at":"2026-10-03","category":"商業分析系列","topic":"商業分析系列","tags":["PharmaEssentia","FormuRx","RNA","LNP"],"summary":"藥華藥（6446）買下予宇生技，交易金額約新台幣1.68億元。依環球生技刊載的公司消息，予宇做的是把RNA送進細胞的遞送研發，帶進來的包括脂質奈米顆粒（LNP）配方、微流體製程、分析、設備與團隊。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"約新台幣1.68億元收購所承接的RNA開發工具與團隊","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-formurx-rna-lnp-acquisition-2026/FIG01_ZH_R3.png"},{"alt":"LNP包封、細胞攝入、內體釋放與mRNA翻譯的開發示意","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-formurx-rna-lnp-acquisition-2026/FIG02_ZH_R3.png"},{"alt":"分列聚合物與LNP遞送受體mRNA的外部前臨床路徑","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-formurx-rna-lnp-acquisition-2026/FIG03_ZH_R6D04.png"},{"alt":"產品與RNA配方、製程、品質和藥效評估的開發能力示意","url":"https://drugnews.com.tw/assets/articles/pharmaessentia-formurx-rna-lnp-acquisition-2026/FIG04_ZH_R6D04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pharmaessentia-formurx-rna-lnp-acquisition-2026/FIG01_ZH_R3.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-03）。藥華藥買下予宇，下一步讓細胞造藥？。https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}